9.02
前日終値:
$8.93
開ける:
$9.0059
24時間の取引高:
22,752
Relative Volume:
0.67
時価総額:
$36.49M
収益:
$147.75M
当期純損益:
$-284.23M
株価収益率:
-3.0785
EPS:
-2.93
ネットキャッシュフロー:
$-317.54M
1週間 パフォーマンス:
+3.68%
1か月 パフォーマンス:
+7.13%
6か月 パフォーマンス:
+60.78%
1年 パフォーマンス:
-45.91%
Fibrogen Inc Stock (FGEN) Company Profile
FGEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
FGEN
Fibrogen Inc
|
9.02 | 36.13M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-26 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-26 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | ダウングレード | Stifel | Buy → Hold |
| 2023-06-26 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | アップグレード | Stifel | Hold → Buy |
| 2023-01-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-09-22 | ダウングレード | Goldman | Neutral → Sell |
| 2021-08-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-07-16 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-03-31 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-03-02 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-01 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-26 | 開始されました | Raymond James | Underperform |
| 2020-07-10 | 再開されました | Stifel | Buy |
| 2020-05-01 | 開始されました | Cowen | Market Perform |
| 2020-04-27 | 開始されました | BofA/Merrill | Neutral |
| 2019-05-29 | 再開されました | Goldman | Neutral |
| 2019-05-10 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | 開始されました | Piper Jaffray | Neutral |
| 2019-02-11 | 再開されました | Stifel | Buy |
| 2018-12-19 | アップグレード | Citigroup | Neutral → Buy |
| 2017-08-08 | 繰り返されました | Leerink Partners | Outperform |
| 2017-08-08 | 繰り返されました | Stifel | Buy |
| 2017-07-21 | ダウングレード | Goldman | Buy → Neutral |
| 2017-07-11 | 開始されました | Jefferies | Buy |
| 2016-02-11 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | 開始されました | Credit Suisse | Neutral |
| 2015-12-04 | 開始されました | Citigroup | Buy |
| 2015-09-23 | 開始されました | Lake Street | Hold |
| 2015-07-29 | 開始されました | Citigroup | Buy |
| 2015-07-20 | アップグレード | Goldman | Neutral → Buy |
| 2014-12-09 | 開始されました | Stifel | Buy |
すべてを表示
Fibrogen Inc (FGEN) 最新ニュース
Quarterly Earnings: Is FibroGen Inc stock a buy before product launchesJuly 2025 Review & Weekly Momentum Picks - moha.gov.vn
FibroGen shares advance after roxadustat earns orphan drug status - MSN
How FibroGen Inc. stock reacts to inflationary pressuresSwing Trade & Real-Time Buy Zone Alerts - Улправда
Published on: 2025-12-20 23:42:14 - Улправда
Why FibroGen Inc. (1FG0) stock attracts HNW investorsRecession Risk & Reliable Breakout Stock Forecasts - Улправда
Why FibroGen Inc. stock is a must watch in 2025July 2025 Selloffs & Precise Buy Zone Identification - DonanımHaber
Is FibroGen Inc. stock a buy before product launchesJuly 2025 Price Swings & Weekly Stock Breakout Alerts - DonanımHaber
FibroGen Q3 2025 Earnings Preview - MSN
Published on: 2025-12-19 15:46:05 - Улправда
Will FibroGen Inc. stock outperform international peers2025 Market Trends & Safe Capital Preservation Plans - Улправда
Published on: 2025-12-18 12:26:14 - Улправда
Is FibroGen (NASDAQ:FGEN) A Risky Investment? - simplywall.st
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS By Investing.com - Investing.com Nigeria
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS - Investing.com India
FibroGen stock rises after roxadustat receives Orphan Drug Designation By Investing.com - Investing.com Nigeria
FibroGen stock rises after roxadustat receives Orphan Drug Designation - Investing.com India
FibroGen (FGEN) Gains FDA Orphan Drug Status for Roxadustat - GuruFocus
Roxadustat granted orphan drug designation for the treatment of myelodysplastic syndromes by the U.S. FDA - marketscreener.com
FibroGen Receives FDA Orphan Drug Designation for Roxadustat in Myelodysplastic Syndromes, Phase 3 Protocol Set for Q4 2025 Submission - Quiver Quantitative
Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration - The Manila Times
Roxadustat Granted Orphan Drug Designation for the - GlobeNewswire
Market Review: Will FibroGen Inc stock keep outperforming rivals2025 Risk Factors & Breakout Confirmation Trade Signals - moha.gov.vn
FibroGen Investor Suit Dismissed Following $28.5 Million Deal - Bloomberg Law News
Can FibroGen Inc. (1FG0) stock deliver strong annual returnsSell Signal & AI Powered Market Entry Strategies - Newser
Will FibroGen Inc. (1FG0) stock outperform global peers2025 Valuation Update & Safe Capital Growth Stock Tips - Newser
FibroGen (FGEN) Stock Analysis Report | Financials & Insights - Benzinga
Is FibroGen Inc. (1FG0) stock overpriced at current multiplesDividend Hike & Weekly Momentum Picks - Newser
How FibroGen Inc. (1FG0) stock reacts to fiscal policiesWeekly Trade Review & Weekly Watchlist for Hot Stocks - Newser
How dovish Fed policy supports FibroGen Inc. (1FG0) stockAnalyst Downgrade & Entry and Exit Point Strategies - Newser
How supply shortages influence FibroGen Inc. (1FG0) stockSell Signal & Weekly Return Optimization Alerts - Newser
Is FibroGen Inc. (1FG0) stock a top hedge fund pick2025 Fundamental Recap & Smart Allocation Stock Tips - Newser
FibroGen, Inc. to Present at Oppenheimer Movers in Rare Disease Summit on December 11, 2025 - Quiver Quantitative
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
Why FibroGen Inc. (1FG0) stock is trending on social mediaJuly 2025 PreEarnings & AI Enhanced Execution Alerts - moha.gov.vn
FibroGen started at buy by H.C. Wainwright - MSN
What valuation multiples suggest for FibroGen Inc. stockWeekly Trade Analysis & Verified Momentum Watchlists - newser.com
Can FibroGen Inc. (1FG0) stock ride next bull market cycle2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Why FibroGen Inc. stock remains resilientPortfolio Return Summary & Real-Time Buy Signal Alerts - newser.com
Can FibroGen Inc. (1FG0) stock deliver consistent EPS growthJuly 2025 Decliners & Weekly Top Gainers Alerts - newser.com
Fibrogen Inc (FGEN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):